Legend Biotech Appoints Alan Bash as President of CARVYKTI®

LEGN 11.04.2024

Full Press ReleaseSEC FilingsOur LEGN Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 12.19.2024 - Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.10.2024 - CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Recent Filings

  • 01.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 144 Report of proposed sale of securities
Newly created position to lead efforts focused on continued growth and sales

SOMERSET, N.J.,Nov. 04, 2024(GLOBE NEWSWIRE) --Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role,Mr. Bashwill be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.

“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from theU.S. Food and Drug AdministrationandEuropean Commissionfor label expansion,” saidYing Huang, Ph.D., Chief Executive Officer ofLegend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”

Mr. Bashserved as Chief Executive Officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as President and CEO atCheckmate Pharmaceuticals. He also had a 23-year career withBristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving theU.S.launch of Opdivo®and the expansion of additional cancer treatments such as Yervoy®and Erbitux®.Mr. Bashcontributed to several blockbuster products in collaboration with other companies, including Abilify®with Otsuka and Eliquis®with Pfizer.

“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” saidMr. Bash. “I am excited about the opportunity to support the continued success of the CARVYKTI franchise and work with theLegend Biotechteam and our collaboration partner, Johnson & Johnson, to fulfill CARVYKTI’s potential to transform the treatment paradigm for multiple myeloma.”

Mr. Bashearned his B.A. fromGeorgetown Universityand his M.B.A. fromColumbia Business School.

AboutLegend BiotechLegend Biotechis a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered inSomerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more atwww.legendbiotech.comand follow us onX (formerly Twitter)andLinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSStatements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in theU.S.litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with theSecurities and Exchange CommissiononMarch 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release.Legend Biotechspecifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:Jessie YeungTel: (732) 956-8271jessie.yeung@legendbiotech.com

PRESS CONTACT:Mary Ann OndishTel: (914) 552-4625media@legendbiotech.com

Primary Logo

Source: Legend Biotech USA Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com